Intellia CFO sells 4,677 shares in preplanned trade

Intellia Therapeutics EVP and CFO Edward J. Dulac III sold 4,677 shares of Common Stock in an open-market transaction.

Accepted by SEC EDGAR 07/06/2026 - 05:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Intellia Therapeutics EVP and CFO Edward J. Dulac III sold 4,677 shares of Common Stock in an open-market transaction. The sale took place on July 2, 2026 at a price of $18.00 per share and was executed under a pre-established Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, Dulac directly holds 156,286 shares of Intellia Therapeutics common stock, indicating he retains a substantial equity stake despite this planned sale.

Insider Trade Summary 10b5-1

Net Seller: 4,677 shares

Net Sell 1 txn

Insider Dulac Edward J III

Role EVP, Chief Financial Officer

Sold 4,677 shs ($84K)

Share of Position Sold 2.9%

Type	Security	Shares	Price	Value
Sale	Common Stock	4,677	$18.00	$84K

Holdings After Transaction: Common Stock — 156,286 shares (Direct)

Holdings Before and After: Common Stock, 160,963 to 156,286 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

Key Figures

Shares sold: 4,677 shares Sale price: $18.00 per share Shares owned after sale: 156,286 shares +1 more

4 metrics

Shares sold 4,677 shares Open-market sale on July 2, 2026

Sale price $18.00 per share Common Stock transaction price

Shares owned after sale 156,286 shares Direct ownership following transaction

Trading plan adoption date September 8, 2025 Rule 10b5-1 plan governing this sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The reported sale of 4,677 shares on this Form 4 occurred automatically"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Intellia Therapeutics (NTLA) report for its CFO?

Intellia Therapeutics reported that EVP and CFO Edward J. Dulac III sold 4,677 shares of Common Stock. The sale occurred at $18.00 per share on July 2, 2026, and was executed as an open-market transaction under a pre-established trading plan.

How many Intellia Therapeutics (NTLA) shares did the CFO sell and at what price?

The CFO sold 4,677 shares of Intellia Therapeutics Common Stock at $18.00 per share. This open-market sale was reported on Form 4 and reflects a single transaction on July 2, 2026, rather than multiple smaller trades.

Was the Intellia Therapeutics (NTLA) CFO’s share sale under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the 4,677-share sale occurred automatically under a Rule 10b5-1 trading plan. That plan was adopted by the reporting person on September 8, 2025, indicating the sale was pre-planned rather than a discretionary market-timing decision.

How many Intellia Therapeutics (NTLA) shares does the CFO hold after the sale?

Following the reported sale, EVP and CFO Edward J. Dulac III directly owns 156,286 shares of Intellia Therapeutics Common Stock. This post-transaction balance, disclosed on the Form 4, shows he continues to maintain a significant personal equity position in the company.

What type of transaction did Intellia Therapeutics (NTLA) disclose for its CFO on Form 4?

The Form 4 discloses an open-market sale of Common Stock by the CFO, coded as transaction type “S.” It involved 4,677 shares at $18.00 per share, with the filing classifying the transaction as a non-derivative, direct ownership sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dulac Edward J III

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET, SUITE 130

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		S(1)		4,677	D	$18	156,286	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

	/s/ James Basta, attorney-in-fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)